Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ortin Global's Free Cash Flow for the
three
months ended in Mar. 2026 was ₹0.00 Mil. Ortin Global's Revenue for the
three
months ended in Mar. 2026 was ₹0.34 Mil. Therefore, Ortin Global's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Ortin Global's FCF Margin % or its related term are showing as below:
NSE:ORTINGLOBE'
s FCF Margin % Range Over the Past 10 Years
Min: -556.82 Med: 0.25 Max: 220.81
Current: -556.82
During the past 13 years, the highest FCF Margin % of Ortin Global was 220.81%. The lowest was -556.82%. And the median was 0.25%.
NSE:ORTINGLOBE's FCF Margin % is ranked worse than 95.72% of 959
companies
in the Drug Manufacturers industry
Industry Median: 2.45
vs NSE:ORTINGLOBE: -556.82
The historical data trend for Ortin Global's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Global's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortin Global FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ortin Global's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Ortin Global's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ortin Global (NSE:ORTINGLOBE) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ortin Global and its competitors. According to the industry distribution chart, Ortin Global ranks #918 out of 959 companies in the Drug Manufacturers industry, placing it in the top 95.7%.
Is Ortin Global's FCF Margin % too high?
Ortin Global's current FCF Margin % is 0.00%. Based on the distribution chart, Ortin Global ranks #918 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ortin Global has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ortin Global's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ortin Global ranks #918 out of 959 companies for FCF Margin %. This places Ortin Global in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ortin Global and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortin Global's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortin Global stock overvalued right now?
Based on GuruFocus' analysis, Ortin Global (NSE:ORTINGLOBE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.37, compared to a current price of ₹15.89 — trading 570.5% above its estimated fair value. The current FCF Margin % is 0.00%. Ortin Global's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Ortin Global (NSE:ORTINGLOBE), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortin Global (NSE:ORTINGLOBE) Overvalued in 2026?
Based on GuruFocus' analysis, Ortin Global stock appears to be overvalued.
The current stock price of ₹15.89 is trading 570.5% above its estimated GF Value™ of ₹2.37.
GuruFocus considers Ortin Global to be Significantly Overvalued.
Key valuation signals for NSE:ORTINGLOBE:
FCF Margin %: 0.00%
GF Value™: ₹2.37 vs. price of ₹15.89 (570.5% above fair value)
No single metric tells the full story. See the NSE:ORTINGLOBE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortin Global Ltd is an Indian company engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helminthics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its API intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zidovudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others. Additionally, the company is also involved in the real estate business.
45GF Score
Get the complete analysis for NSE:ORTINGLOBE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ORTINGLOBE has been successfully added to your 
